Anti-tumour necrosis factor therapy in rheumatoid arthritis: an update on safety

Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

2001 • 3,631 citations

Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis

2000 • 2,992 citations

Adverse drug reactions: definitions, diagnosis, and management

2000 • 2,723 citations

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

1999 • 2,358 citations

A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate

1999 • 2,117 citations

A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

2000 • 1,757 citations

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

2003 • 1,750 citations

Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure

2003 • 1,504 citations

Etanercept Therapy in Rheumatoid Arthritis

1999 • 1,407 citations

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

1989 • 1,269 citations

Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis

2003 • 1,223 citations

Frequency of infection in patients with rheumatoid arthritis compared with controls: A population‐based study

2002 • 1,186 citations

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active‐surveillance report

2003 • 1,009 citations

Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart

1996 • 993 citations

TNF neutralization in MS

1999 • 968 citations

Demyelination occurring during anti-tumor necrosis factor ? therapy for inflammatory arthritides

2001 • 813 citations

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

2003 • 747 citations

Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration

2002 • 668 citations

Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein

2001 • 569 citations

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

2003 • 498 citations

Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist

2003 • 450 citations

Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept

2002 • 444 citations

Safety and Efficacy of a Soluble P75 Tumor Necrosis Factor Receptor (Enbrel, Etanercept) in Patients With Advanced Heart Failure

1999 • 397 citations

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α–neutralizing agents

2003 • 380 citations

Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy

2003 • 334 citations

Onset of multiple sclerosis associated with anti-TNF therapy

2001 • 316 citations

All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database.

2003 • 288 citations

Infections and anti–tumor necrosis factor α therapy

2003 • 283 citations

The molecular action of tumor necrosis factor-alpha

1991 • 279 citations

Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems

1993 • 272 citations

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden

2002 • 259 citations

CAUSE OF DEATH IN RHEUMATOID ARTHRITIS

1984 • 252 citations

Histoplasmosis after Treatment with Anti–Tumor Necrosis Factor-α Therapy

2003 • 233 citations

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

1999 • 232 citations

Increased risk of tuberculosis in patients with rheumatoid arthritis.

2003 • 224 citations

Limitations and strengths of spontaneous reports data

1998 • 222 citations

Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.

2000 • 197 citations

Anti-TNF-?-induced systemic lupus syndrome

2003 • 187 citations

Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.

2003 • 174 citations

Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice.

1999 • 146 citations

Fatal Sepsis in a Patient With Rheumatoid Arthritis Treated With Etanercept

2001 • 129 citations

Leukocytoclastic vasculitis due to etanercept.

2000 • 123 citations

Experience with etanercept in an academic medical center: Are infection rates increased?

2002 • 122 citations

The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea.

2002 • 119 citations

Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis

2002 • 116 citations

Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis

2003 • 116 citations

Pulmonary Cryptococcosis After Initiation of Anti-Tumor Necrosis Factor-α Therapy

2003 • 112 citations

Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: Continued observations

2003 • 107 citations

Fatal Sepsis in a Patient With Rheumatoid Arthritis Treated With Etanercept

2001 • 104 citations

Invasive Pulmonary Aspergillosis Soon After Therapy With Infliximab, a Tumor Necrosis Factor-Alpha–Neutralizing Antibody: A Possible Healthcare-Associated Case?

2003 • 98 citations

Anti–tumor necrosis factor therapies

2001 • 96 citations

Drug points: Bilateral anterior toxic optic neuropathy and the use of infliximab

2003 • 88 citations

Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate

2003 • 86 citations

Drug-induced lupus following treatment with infliximab in rheumatoid arthritis

2002 • 86 citations

New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis

2002 • 85 citations

Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis

2002 • 84 citations

Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab.

2002 • 76 citations

Etanercept-induced systemic lupus erythematosus

2003 • 76 citations

Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment

2002 • 73 citations

Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.

2002 • 70 citations

Aplastic anemia following administration of a tumor necrosis factor‐α inhibitor

2003 • 68 citations

Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit

2004 • 68 citations

Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies.

1997 • 66 citations

Multiple bilateral eyelid molluscum contagiosum lesions associated with TNFα-antibody and methotrexate therapy

2002 • 62 citations

Anti–tumor necrosis factor α therapy and the risk of lymphoma in rheumatoid arthritis: No clear answer

2004 • 61 citations

Concurrence of rheumatoid arthritis and systemic lupus erythematosus: report of 11 cases.

1987 • 60 citations

Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis

2002 • 48 citations

Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis

2002 • 44 citations

Progressive outer retinal necrosis in immunocompetent patients treated initially for optic neuropathy with systemic corticosteroids

2003 • 42 citations

The role of TNFalpha and lymphotoxin in demyelinating disease

1999 • 42 citations

Coexistent rheumatoid arthritis and systemic lupus erythematosus: clinical, serological, and phenotypic features.

1992 • 41 citations

The use of infliximab in academic rheumatology practice: an audit of early clinical experience.

2002 • 40 citations

Mycobacterium marinum Tenosynovitis in a Patient on Etanercept Therapy for Rheumatoid Arthritis

2002 • 38 citations

Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland.

2002 • 37 citations

Mycobacteria tuberculosis peritonitis associated with etanercept therapy.

2003 • 35 citations

Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system

2000 • 31 citations

Orbital myositis in a rheumatoid arthritis patient during etanercept treatment.

2003 • 31 citations

Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid.

2003 • 30 citations

Lymphoma development in a patient receiving anti-TNF therapy.

2003 • 25 citations

Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.

2000 • 22 citations

Panniculitis

2003 • 15 citations

[Fatal miliary tuberculosis during treatment with infliximab].

2002 • 10 citations

Post-mortem collection of human joint tissues for research

2003 • 10 citations

Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems

1994 • 8 citations

Neck Mass in a Rheumatoid Arthritis Patient Taking Etanercept

2000 • 4 citations